Search research articles
Contact Us
Filters
Showing results (1-10 of 157) with videos related to
Page
of 16
Sort By:
Endocrine, Metabolic & Immune Disorders Drug Targets
|
October 28, 2009
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification
Karine Breckpot, David Escors
Frontiers in Immunology
|
September 27, 2018
The Journey of <i>in vivo</i> Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
Cleo Goyvaerts, Karine Breckpot
Nature Biomedical Engineering
|
April 3, 2019
Towards a personalized iPSC-based vaccine
Cleo Goyvaerts, Karine Breckpot
Archivum Immunologiae Et Therapiae Experimentalis
|
February 10, 2010
Lentiviral vectors in gene therapy: their current status and future potential
David Escors, Karine Breckpot
Journal of Immunology Research
|
November 20, 2015
Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines
Cleo Goyvaerts, Karine Breckpot
Frontiers in Cell and Developmental Biology
|
August 17, 2019
Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Ken Maes, Karine Breckpot
International Review of Cell and Molecular Biology
|
January 15, 2024
Novel technologies for applying immune checkpoint blockers
Robin Maximilian Awad, Karine Breckpot
Immunotherapy
|
May 11, 2011
mRNA: delivering an antitumor message?
Sandra Van Lint, Kris Thielemans, Karine Breckpot
Current Gene Therapy
|
December 17, 2008
Lentiviral vectors for anti-tumor immunotherapy
Karine Breckpot, Perpetua U Emeagi, Kris Thielemans
Oncoimmunology
|
November 20, 2012
The role of SMAC mimetics in regulation of tumor cell death and immunity
Perpetua U Emeagi, Kris Thielemans, Karine Breckpot
Page
of 16
Search research articles
Search
Showing results (1-10 of 157) with videos related to
Sort By:
Page
of 16
Endocrine, Metabolic & Immune Disorders Drug Targets
|
October 28, 2009
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification
Karine Breckpot, David Escors
Frontiers in Immunology
|
September 27, 2018
The Journey of <i>in vivo</i> Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
Cleo Goyvaerts, Karine Breckpot
Nature Biomedical Engineering
|
April 3, 2019
Towards a personalized iPSC-based vaccine
Cleo Goyvaerts, Karine Breckpot
Archivum Immunologiae Et Therapiae Experimentalis
|
February 10, 2010
Lentiviral vectors in gene therapy: their current status and future potential
David Escors, Karine Breckpot
Journal of Immunology Research
|
November 20, 2015
Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines
Cleo Goyvaerts, Karine Breckpot
Frontiers in Cell and Developmental Biology
|
August 17, 2019
Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Ken Maes, Karine Breckpot
International Review of Cell and Molecular Biology
|
January 15, 2024
Novel technologies for applying immune checkpoint blockers
Robin Maximilian Awad, Karine Breckpot
Immunotherapy
|
May 11, 2011
mRNA: delivering an antitumor message?
Sandra Van Lint, Kris Thielemans, Karine Breckpot
Current Gene Therapy
|
December 17, 2008
Lentiviral vectors for anti-tumor immunotherapy
Karine Breckpot, Perpetua U Emeagi, Kris Thielemans
Oncoimmunology
|
November 20, 2012
The role of SMAC mimetics in regulation of tumor cell death and immunity
Perpetua U Emeagi, Kris Thielemans, Karine Breckpot
Page
of 16